10-QHealthcare

Pacira Biosciences, Inc.

PCRX · Period ending 2026-09-30 · Filed 2026-11-05 · Updated

In short

Pacira Biosciences, Inc. (PCRX) has revenue up 3.6% to $726.4M and net income up 107.1% to $7.0M year on year. Its net margin is 1.0%, and it trades at 39.2× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$36.48

P/E (TTM)

39.2x

Price ÷ earnings per share

P/B

2.0x

Price ÷ book value

P/S (TTM)

2.0x

Price ÷ revenue per share

Beta

0.22

Low volatility vs market

PEG Ratio

1.0x

P/E ÷ earnings growth rate

52-Week Range

$18.80$36.48 now$36.67

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

PCRX vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.1%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — PCRX

Inflationary Boom
✦

Strengths

  • EPS (Diluted): $0.16 (+107.4% YoY) — Earnings per share rose 107% — each share earned more.

  • Net Income: $7.0M (+107.1% YoY) — Profit grew 107% — the company kept more of each dollar earned.

◈

Weaknesses

  • Operating Cash Flow: $152.0M (-19.7% YoY) — Operating cash flow fell 20% but remained positive.

  • Total Assets: $1.3B (-18.6% YoY) — Total assets shrank 19% — the balance sheet contracted.

  • Stock is near its 52-week high (36.67) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

◎

Opportunities

  • Revenue: $726.4M (+3.6% YoY) — Revenue grew 4% — the company sold more goods or services than the prior year.

⚠

Threats

No significant threats flagged.

Year-over-Year Changes

EPS (Diluted)

$0.16

was $-2.15

+107.4%

Earnings per share rose 107% — each share earned more.

Net Income

$7.0M

was -$99.6M

+107.1%

Profit grew 107% — the company kept more of each dollar earned.

Operating Cash Flow

$152.0M

was $189.4M

−19.7%

Operating cash flow fell 20% but remained positive.

Total Assets

$1.3B

was $1.6B

−18.6%

Total assets shrank 19% — the balance sheet contracted.

Revenue

$726.4M

was $701.0M

+3.6%

Revenue grew 4% — the company sold more goods or services than the prior year.

Risk Flags

0 high · 0 medium · 1 low
  • ○ Low

    Stock is near its 52-week high (36.67) — the price reflects strong recent momentum, but entry risk is elevated at these levels.

Technical Signals

Daily closes · 1-year data

Pacira Biosciences, Inc.: common questions

Is Pacira Biosciences, Inc. profitable?

Yes. Pacira Biosciences, Inc. made a net profit of $7M in its latest fiscal year (fiscal 2025), a net margin of 1.0%.

Is Pacira Biosciences, Inc.'s revenue growing?

Yes. Revenue grew 3.6% year on year, to $726.4M.

What is Pacira Biosciences, Inc.'s P/E ratio?

Pacira Biosciences, Inc. trades at 39.2× its trailing twelve-month earnings. In other words, the share price is about 39 times the profit per share the company earned over the past year.

Does Pacira Biosciences, Inc. pay a dividend?

No dividend is currently expected from Pacira Biosciences, Inc., according to the latest market data.

Answers are generated from the figures in this report (updated 7 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — PCRX

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade PCRX

Links open broker research pages. Not an endorsement or recommendation.

Research Pacira Biosciences, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.